News
-
Review concluded regarding general reimbursement for Valsartan/Hydrochlorothiazide "Actavis"
| 08 March 2012 |
We have completed our review of an application for general reimbursement for Valsartan/Hydrochlorothiazide "Actavis". The product is neither eligible for general nor general conditional reimbursement.
-
Comments received on the reassessment of reimbursement status of antidiabetic medicines (ATC group A10)
| 06 March 2012 |
The Danish National Board of Health has received a number of comments from stakeholders about the Reimbursement Committee's discussion of the reimbursement status of antidiabetic medicines (ATC group A10).
-
Decision on general conditional reimbursement for alendronate-containing medicines
| 22 February 2012 |
In cooperation with the Reimbursement Committee, we have decided to grant alendronate-containing medicines general conditional reimbursement from 5 March 2012. Reimbursement is conditional as it is reserved for patients with low-energy hip fractures. For any other patients who are treated with alendronate, the doctor must apply for single reimbursement, and the guiding criteria for single reimbursement remain unchanged for these patients. Alendronate is used for the treatment of osteoporosis (brittle bones).
-
Changed criteria for single reimbursement for osteoporosis medicines other than alendronate
| 22 February 2012 |
As of 5 March 2012, it will only be possible to obtain a single reimbursement grant for the other medicines used in osteoporosis treatment for patients that cannot use alendronate. The criteria for single reimbursement are changed because of the large price gaps between the different medicines, where the reimbursement price of alendronate is by far the lowest.
-
Applications for general reimbursement in 2011
| 02 February 2012 |
In 2011, we reviewed 21 applications for general reimbursement for 20 different medicinal products. 15 of the applications ended with the granting of general reimbursement or general conditional reimbursement, and the remaining six applications were refused.
-
Review concluded regarding general reimbursement for Xarelto®
| 25 January 2012 |
The Danish Medicines Agency has completed its review of an application for general reimbursement for two new strengths of Xarelto®. The product maintains general reimbursement.
-
Review concluded regarding general reimbursement for Zomig Nasal®
| 20 January 2012 |
The Danish Medicines Agency has completed its review of an application for general reimbursement for Zomig Nasal®. The product has been granted general reimbursement.
-
Decision on general reimbursement for Yellox®
| 17 January 2012 |
The Danish Medicines Agency has completed its review of an application for general reimbursement for Yellox®. The product has been granted general reimbursement.
-
Review concluded regarding general reimbursement for Multaq®
| 16 January 2012 |
The Danish Medicines Agency has completed its review of an application for general reimbursement for Multaq®. The product is neither eligible for general nor general conditional reimbursement.
-
Reassessment of reimbursement status of antidiabetic medicines (ATC group A10)
| 13 January 2012 |
On 22 December 2009, the Danish Medicines Agency announced that we would begin our reassessment of the reimbursement status of a number of groups of medicines, including antidiabetics (ATC group A10). Within a few months, the Reimbursement Committee will begin to discuss the reimbursement status of antidiabetics.
-
Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of strong painkillers (opioids)
| 05 January 2012 |
At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group N02A, opioids, as well as certain medicines in ATC groups N07BC and R05DA.